Vanda PharmaceuticalsVNDA
About: Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Employees: 368
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
23% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 43
23% more call options, than puts
Call options by funds: $261K | Put options by funds: $212K
0% more capital invested
Capital invested by funds: $206M [Q3] → $207M (+$211K) [Q4]
1.52% less ownership
Funds ownership: 75.53% [Q3] → 74.01% (-1.52%) [Q4]
4% less funds holding
Funds holding: 151 [Q3] → 145 (-6) [Q4]
12% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 25
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Raghuram Selvaraju 30% 1-year accuracy 99 / 331 met price target | 383%upside $20 | Buy Reiterated | 1 Apr 2025 |
Financial journalist opinion









